Putney Launches Carprofen Chewable Tablets

NewSpring Healthcare

Expects Rapid Penetration of $70m Rimadyl® Chewable Tablets Market

Portland, ME—December 18, 2014—Putney, Inc., a rapidly growing pharmaceutical company focused on the development and sale of generic prescription medicines for pets, announces today that it is launching Putney Carprofen Chewable Tablets, its FDA approved generic of Zoetis’ popular Rimadyl® Chewable Tablets. With this product approval, the Company’s fourth in less than three months, Putney is the only company with FDA approved generics of all three dosage forms of carprofen products – Putney Carprofen Chewable Tablets, Putney Carprofen Sterile Injectable Solution, and Putney Carprofen Caplets. Putney’s other recent FDA approvals include Putney Dexmedetomidine HCl, a first-to-market generic of Dexdomitor® and the Company’s third approval of a first-to-market generic in less than two years. Putney launched first-to-market Putney Cefpodoxime Proxetil Tablets (generic of Simplicef®) and first-to-market Putney Enrofloxacin Flavored Tablets (generic of Baytril® Taste Tabs®) in 2013.

Putney expects to penetrate and expand the $70 million carprofen chewable tablet market rapidly as veterinarians opt to save approximately 30% on Putney’s bioequivalent product (compared to Rimadyl® Chewable Tablets current list price). The number of carprofen caplet units sold through veterinarians increased threefold as generic carprofen caplets gained market share1, indicating more pets were treated when veterinarians had an affordable generic option. Generics now account for over 80% of carprofen caplets dispensed by veterinarians.

Jean Hoffman, president and CEO of Putney, says she expects a similar expansion of the carprofen chewable market with the introduction of Putney’s Carprofen Chewable Tablets. “Pet owners faced with the expense of a long term medicine for a chronic condition wish they could afford to comply with their veterinarian’s recommendation to give their pet the recommended medicine every day, but the expense of many pet drugs is a problem.  Now that Putney offers affordable Carprofen Chewable Tablets through veterinarians, pet owners can afford to take care of their beloved pet family members. Veterinarians who provide Putney’s affordable generics can increase pet owner trust that they are doing the right thing for their clients, and keep satisfied pet owners coming back to their practices,” says Hoffman.        

“All veterinarians can gain the benefits of a generic for their pet owners and pet patients, by ordering direct from Putney or through our network of distributor partners, even if their usual distributor is blocked by Zoetis from carrying our products,” says Hoffman. For more information about Putney products, including prescribing and safety information, and about Putney’s distribution partners for its Carprofen Chewable Tablets, visit www.PutneyVet.com

Based on Putney analysis of market data

PUTNEY® and logo are registered trademarks of Putney, Inc. ©2014 Putney, Inc. All other marks are the property of their respective owners.

Important Safety Information: As with other NSAIDs, signs of Carprofen intolerance may include appetite loss, vomiting and diarrhea, which could indicate side effects involving the digestive tract, liver or kidneys. Some of these side effects, in rare situations, may be serious, resulting in hospitalization or even death. Pet owners should be advised to discontinue treatment if side effects occur and contact their veterinarian. Concomitant use of Putney Carprofen Chewable Tablets with other anti-inflammatory drugs, such as other NSAIDs or corticosteroids, should be avoided because of the potential increase of adverse reactions. Please see the package insert and “Dog Owner Information Sheet” for further safety and usage information.

About Putney

Putney is a pharmaceutical company committed to providing high quality, cost-effective generic medicines for pets. Putney’s reliable supply of affordable drug options empowers veterinarians, allowing them to provide the best possible medicine at the best possible price, and supports pet owners, helping them afford to comply with veterinary recommendations. Putney’s ongoing investment in research and development is focused on creating the next generation of generic veterinary products based on inputs from companion animal veterinarians and its industry partners. Learn more at www.PutneyVet.com.